Davita Inc vs Royal Caribbean Cruises Ltd — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Royal Caribbean Cruises Ltd trades at $307.2 (market cap $82.38B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 7× Davita Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.62% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RCL | |
|---|---|---|
Market Cap | $11.72B | $82.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $365.84 |
52-Week Low | $103.87 | $246.71 |
Enterprise Value | $24.44B | $105.02B |
Dividend Yield | — | 1.62% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Royal Caribbean Group (RCL) trades at $320, down 0.17% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by robust earnings beats, with Q2 2026 EPS of $4.21 exceeding the $3.98 estimate, and a consensus analyst price target of $343.09 implying upside. Recent news highlights strong demand, fleet expansion, and a $1.25 billion senior notes offering to fund growth, while cash flow trends show improving operational strength.
The outlook for RCL remains positive, driven by record bookings, pricing power, and strategic investments, though risks include geopolitical impacts on European itineraries, high debt levels, and premium valuations. Investors should weigh the company's solid execution against macroeconomic and industry-specific headwinds for balanced exposure.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →